Sana Biotechnology Announces Five Presentations at the 65th American Society of Hematology Annual Meeting
November 02 2023 - 9:05AM
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on
changing the possible for patients through engineered cells, today
announced that five abstracts will have poster presentations
at the 65th American Society of Hematology Annual Meeting to be
held December 9-12, 2023 in San Diego, CA.
Details of
the poster presentations are as follows: |
|
|
Title: |
Hypoimmune, Allogeneic
CD22-Directed CAR T Cells That Evade Innate and Adaptive
Immune Rejection for the Treatment of Large B Cell Lymphoma
Patients That Are Relapsed/Refractory to CD19-Directed CAR T
Cell Therapy |
Abstract
Number: |
3437 |
Session
Name: |
703. Cellular Immunotherapies:
Basic and Translational: Poster II |
Session
Date: |
Sunday, December 10, 2023 |
Presentation
Time: |
6:00 PM - 8:00 PM |
Location: |
San Diego Convention Center,
Halls G-H |
|
|
|
|
Title: |
Efficient and Specific In Vivo
Genetic Engineering of Human Hematopoietic Stem Progenitor
Cells without Selective Conditioning |
Abstract
Number: |
2252 |
Session
Name: |
801. Gene Therapies: Poster
I |
Session
Date: |
Saturday, December 9, 2023 |
Presentation
Time: |
5:30 PM - 7:30 PM |
Location: |
San Diego Convention Center,
Halls G-H |
|
|
|
|
Title: |
Development of a Novel,
Allogeneic GPRC5D-Directed CAR for Treatment of Multiple
Myeloma Patients |
Abstract
Number: |
3290 |
Session
Name: |
651. Multiple Myeloma and Plasma
Cell Dyscrasias: Basic and Translational: Poster II |
Session
Date: |
Sunday, December 10, 2023 |
Presentation
Time: |
6:00 PM - 8:00 PM |
Location: |
San Diego Convention Center,
Halls G-H |
|
|
|
|
Title: |
In Vitro and In
Vivo Specificity and Biodistribution of a Novel CD8-Targeted
Fusosome |
Abstract
Number: |
3630 |
Session
Name: |
801. Gene Therapies: Poster
II |
Session
Date: |
Sunday, December 10, 2023 |
Presentation
Time: |
6:00 PM - 8:00 PM |
Location: |
San Diego Convention Center,
Halls G-H |
|
|
|
|
Title: |
Feasibility of Extracorporeal
Delivery of Fusosomes to Generate CAR T Cells In Vivo |
Abstract
Number: |
3631 |
Session
Name: |
801. Gene Therapies: Poster
II |
Session
Date: |
Sunday, December 10, 2023 |
Presentation
Time: |
6:00 PM - 8:00 PM |
Location: |
San Diego Convention Center,
Halls G-H |
Full abstracts are available for online viewing via the ASH
Annual Meeting website at Hematology.org.
About Sana BiotechnologySana Biotechnology,
Inc. is focused on creating and delivering engineered cells as
medicines for patients. We share a vision of controlling genes,
replacing missing or damaged cells, and making our therapies
broadly available to patients. We are a passionate group of people
working together to create an enduring company that changes how the
world treats disease. Sana has operations in Seattle, Cambridge,
South San Francisco, and Rochester. For more information about Sana
Biotechnology, please visit https://sana.com/.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements about Sana Biotechnology, Inc. (the “Company,” “we,”
“us,” or “our”) within the meaning of the federal securities laws,
including those related to the Company’s vision; expectations for
the Company’s participation at the 65th American Society of
Hematology Annual Meeting; and expectations for the Company’s
presentations at such meeting, including the content of such
presentations. All statements other than statements of historical
facts contained in this press release, including, among others,
statements regarding the Company’s strategy, expectations, cash
runway and future financial condition, future operations, and
prospects, are forward-looking statements. In some cases, you can
identify forward-looking statements by terminology such as “aim,”
“anticipate,” “assume,” “believe,” “contemplate,” “continue,”
“could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,”
“may,” “objective,” “plan,” “positioned,” “potential,” “predict,”
“seek,” “should,” “target,” “will,” “would” and other similar
expressions that are predictions of or indicate future events and
future trends, or the negative of these terms or other comparable
terminology. The Company has based these forward-looking statements
largely on its current expectations, estimates, forecasts and
projections about future events and financial trends that it
believes may affect its financial condition, results of operations,
business strategy and financial needs. In light of the significant
uncertainties in these forward-looking statements, you should not
rely upon forward-looking statements as predictions of future
events. These statements are subject to risks and uncertainties
that could cause the actual results to vary materially, including,
among others, the risks inherent in drug development such as those
associated with the initiation, cost, timing, progress and results
of the Company’s current and future research and development
programs, preclinical and clinical trials, as well as economic,
market and social disruptions. For a detailed discussion of the
risk factors that could affect the Company’s actual results, please
refer to the risk factors identified in the Company’s SEC reports,
including but not limited to its Quarterly Report on Form 10-Q
dated August 3, 2023. Except as required by law, the Company
undertakes no obligation to update publicly any forward-looking
statements for any reason.
Investor Relations & Media:Nicole
Keithinvestor.relations@sana.commedia@sana.com
Sana Biotechnology (NASDAQ:SANA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sana Biotechnology (NASDAQ:SANA)
Historical Stock Chart
From Apr 2023 to Apr 2024